Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 8/20 | 0.65 |
| ▸ | PPARG | P37231 | 2/20 | 0.57 |
| ▸ | PPARD | Q03181 | 2/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GPR6 | P46095 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6358241 | 0.93 | ALB (0.64) | ALBPPARGPPARDPPARASMN1; SMN2 | |
| SCHEMBL6352516 | 0.91 | ALB (0.62) | ALBPPARGPPARDPPARASMN1; SMN2 | |
| SCHEMBL6355451 | 0.89 | ALB (0.67) | ALBPPARGPPARDPPARASMN1; SMN2 | |
| SCHEMBL6352236 | 0.87 | PPARG (0.58) | ALBPPARGPPARDPPARASMN1; SMN2 | |
| SCHEMBL6354039 | 0.86 | TP53 (0.69) | ALBPPARGPPARDPPARASMN1; SMN2 | |
| SCHEMBL6359330 | 0.86 | TP53 (0.72) | ALBPPARGPPARDPPARASMN1; SMN2 | |
| SCHEMBL6353328 | 0.86 | ALB (0.81) | ALBMEN1KMT2ATP53THRB | |
| SCHEMBL6350731 | 0.86 | TP53 (0.71) | ALBPPARGPPARDPPARASMN1; SMN2 | |
| SCHEMBL6358764 | 0.86 | TP53 (0.71) | ALBPPARGPPARDPPARASMN1; SMN2 | |
| SCHEMBL6352302 | 0.85 | ALB (0.59) | ALBPPARGPPARDPPARAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | claimed |
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | ALB 1682/4885PPARG 3572/4885PPARD 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.